Author

Kedar GC

Institution: Ambrx (United States)

Observed institution: Ambrx (United States)

ORCID: 0009-0005-5332-2155

Observed ORCID: 0009-0005-5332-2155

OpenAlex ID: A5094221961

Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer

2024 · Lillian K. Skidmore, David Mills, et al. · Molecular Cancer Therapeutics · 24

Abstract 6352: Preclinical discovery of ARX622: A site-specific, TLR7 agonist, HER2-targeted immune-stimulatory antibody drug conjugate for treatment of multiple solid tumor types

2024 · David Mills, Ji Young Kim, et al. · Cancer Research · 1

Data from Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer

2024 · Lillian K. Skidmore, David Mills, et al.

Table S1 from Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer

2024 · Lillian K. Skidmore, David Mills, et al.

Works count: 4

Citation count: 25

H-index: 1

I10-index: 1